back to US directory
us clinical guidance

Psoriasis assessment and treatment selection

AAD鈥揘PF assessment of cutaneous psoriasis, high-impact sites, psoriatic arthritis, comorbidity, topical care and specialist escalation in US practice.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children and adults with suspected or established cutaneous psoriasis. Generalized pustular psoriasis, erythroderma and unstable systemic illness are acute-care conditions.
sources for this section:AAD鈥揘PF psoriasis guideline

The Bottom Line

  • Confirm a compatible morphology and distribution, then assess body-surface area, a practical physician global measure, symptoms, nails, scalp, genitals, palms and soles, because limited surface area can still cause severe functional or psychosocial impact.
  • Ask regularly about inflammatory joint symptoms and screen for psoriatic arthritis; delayed recognition can permit irreversible joint damage and may alter systemic-treatment selection.
  • For plaque psoriasis outside intertriginous areas, topical corticosteroids are recommended; vitamin D analogs, tazarotene and calcineurin inhibitors can reduce steroid exposure or support sensitive-site and long-term strategies.
  • Escalate beyond topical care when disease is extensive, functionally or psychologically high impact, involves difficult sites, or remains uncontrolled; phototherapy, nonbiologic systemic medicines and biologics require source- and patient-specific review.
  • Assess associated cardiometabolic disease, smoking, alcohol, inflammatory bowel disease and mental health, and coordinate care because comorbidity affects both prognosis and treatment choice.
sources for this section:AAD鈥揘PF psoriasis guideline

Practical clinical workflow

1
Record phenotype, sites, body-surface area, symptom burden, previous treatments, infection triggers, medicines, smoking, alcohol, cardiovascular risk, mood and family history; photograph or use a consistent severity measure for follow-up.
2
Ask about morning stiffness, swollen joints, dactylitis, heel pain and inflammatory back symptoms, and refer suspected psoriatic arthritis promptly rather than waiting for severe skin disease.
3
For localized plaque disease, choose a site-appropriate topical corticosteroid and steroid-sparing partner, give explicit quantity and duration instructions, and avoid high-potency exposure on thin or occluded skin.
4
Review response, adherence and adverse effects, then discuss phototherapy or systemic referral when topical care is insufficient or impractical; consider pregnancy, infection, malignancy, hepatic, renal and cardiovascular context before systemic selection.
5
Maintain longitudinal screening for cardiometabolic and psychological comorbidity and monitor the exact therapy used; treatment success includes symptoms and life impact, not clearing a trial-oriented PASI score alone.
sources for this section:AAD鈥揘PF psoriasis guideline

Safety boundaries and escalation

  • Diffuse erythema with systemic instability, thermoregulatory failure or high-output physiology suggests erythrodermic psoriasis and requires emergency assessment.
  • Generalized pustules with fever, pain, dehydration or systemic illness can represent generalized pustular psoriasis and needs urgent specialist or hospital care.
  • Avoid abrupt withdrawal of systemic corticosteroid exposure where it may destabilize psoriasis, and do not start immunosuppression without infection, vaccine and medicine-specific safety review.
  • A hot swollen joint, rapidly progressive inflammatory arthritis or new ocular inflammation requires urgent diagnosis rather than routine skin follow-up.
sources for this section:AAD鈥揘PF psoriasis guideline

Localization

The AAD鈥揘PF guideline set is the US source for this summary. Its biologic and nonbiologic sections are being updated, so current FDA labeling and the final new AAD鈥揘PF publications must be checked before a systemic decision.
sources for this section:AAD鈥揘PF psoriasis guideline

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Academy of Dermatology and National Psoriasis FoundationPsoriasis clinical guidelineCurrent topic-specific guideline set; biologic and nonbiologic update in development 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.